Angiotensin converting enzyme (ACE) inhibitors and dihydropyridine calcium antagonists are well established and widely used as monotherapy in patients with mild to moderate essential hypertension. Earlier studies combining short acting drugs from these classes require multiple dosing and were associated with poor compliance. Availability of longer acting compounds allows once daily administration to avoid the inconvenience of a multiple daily dose. It was decided to perform a randomised double blind, crossover study with the long acting calcium channel blocker amlodipine and the long acting ACE inhibitor lisinopril, given either alone or in combination in essential hypertension. Twenty four patients with diastolic blood pressure (DBP) between 95 and 104 mm Hg received amlodipine 2.5 mg and 5 mg, lisinopril 5 mg and 10 mg, and their combination as per a prior randomisation schedule. Supine and standing blood pressure and heart rate were recorded at weekly intervals. Higher doses of both the drugs individually or in combination were used if the target supine DBP below 90 mm Hg was not achieved. There was a significant additional blood pressure lowering eVect with the combination when compared either with amlodipine or lisinopril alone. Five mg amlodipine and 10 mg lisinopril monotherapy achieved the target blood pressure in 71% and 72% patients respectively. The combination of 2.5 mg amlodipine with 5 mg lisinopril produced a much more significant lowering of blood pressure in a higher percentage of patients than that with an individual low dose. (Postgrad Med J 2000;76:350-353) 
It is well known that monotherapy does not provide therapeutic response in all hypertensives. Some patients show an excellent response, while in others there is a poor response. Combination antihypertensive therapy is administered when blood pressure is inadequately controlled by monotherapy to achieve a balanced and additive antihypertensive eVect with minimum adverse eVects. 1 Until recently, combination therapy generally employed a diuretic, but the availability of new classes of drugs and improved agents within the existing classes now provides a multitude of potential drug combinations. 1 Proper understanding of the underlying mechanism by which the various classes of antihypertensive drugs act together provides the rationale of developing eVective combinations. 2 Both angiotensin converting enzyme (ACE) inhibitors and dihydropyridine calcium antagonists are well established and widely used in monotherapy. An understanding of diVerences in the mechanism of action of these agents allows a logical approach for the use of these agents as a combination therapy. Calcium antagonists are vasodilatory and tend to increase plasma renin, therefore combination with an ACE inhibitor is theoretically sound. 3 Furthermore, calcium antagonists of the dihydropyridine group have been shown to have a diuretic and natriuretic eVect, which again should combine well with ACE inhibitors. 4 Calcium antagonists and ACE inhibitors in combination reduce blood pressure more than either drug alone. 4 Regardless of the order of administration, the combination of nifedipine and captopril was found to be significantly more eVective than the individual agents. 5 However the eVect was short lived due to the short duration of action of both the drugs. Therapy with 5 mg enalapril and 5 mg felodipine produced a significant decrease in both supine and erect blood pressure. 6 Longer acting compounds of both classes, like amlodipine and lisinopril, have now become available allowing once daily administration.
The aim of the present study was to compare in a double blind, randomised, crossover design, the eYcacy and safety of the long acting calcium channel antagonist amlodipine and the long acting ACE inhibitor lisinopril, individually and in combination in mild to moderate hypertension.
Patients and methods
Patients presenting to the outpatient department with mild to moderate hypertension, with a supine diastolic blood pressure (DBP) between 95 and 104 mm Hg, after two weeks oV all antihypertensive treatment, and found to have no secondary cause of hypertension, were enrolled. Patients with renal and hepatic impairment, ischaemic heart disease, cerebrovascular disease, diabetes mellitus, pregnant women, or those who were taking oral contraceptives were excluded from the study. Before inclusion into the present study protocol, regular measurement of blood pressure was carried out at weekly intervals for four weeks. Patients gave their written informed consent for their participation in this institutional ethics committee approved study. A total of 30 patients (16 male and 14 female) fulfilled the inclusion and exclusion criteria and were included in the study.
After four weeks of a placebo run in phase, patients entered in the double blind, randomised crossover study phase. Patients were randomised to receive initially amlodipine or lisinopril and then their combination. Each active drug treatment period lasted for four weeks. In monotherapy, amlodipine was used in the dose of 2.5 mg daily for two weeks, the dose was increased to 5 mg daily for patients in whom the supine DBP was above 90 mm Hg. The other group received lisinopril 5 mg daily for two weeks, then increased to 10 mg daily if supine DBP was more than 90 mm Hg. For combination therapy, treatment was started with 2.5 mg amlodipine and 10 mg lisinopril per day. If after two weeks, the supine DBP was more than 90 mm Hg, a combination of 5 mg amlodipine and 10 mg lisinopril was used. Blood pressure was measured at each visit between 9 am and 10 am, 24 hours after the previous dose.
The supine (10 min) and standing (2 min) blood pressure were determined with appropriate cuV size by the same observer using L&T Minimon 7133 A blood pressure monitor and the mean of three readings was noted. Pulse rate was recorded simultaneously using a L&T Micromon 7142 pulse monitor. Patients were asked if there had been any change in their presenting symptoms or development of new symptoms at each follow up visit.
Patients were instructed to return unused medications at each follow up visit to know the compliance. Antihypertensive eYcacy between the treatment schedules was compared using analysis of variance and the paired t test.
Results
Patients who received even a single dose of active treatment were included in this intentto-treat analysis to compare the eVect of various phases of treatment phases. A total of 30 patients (16 males and 14 females), mean (SD) age 49.8 (9.0) years (range 41-62 years), were enrolled. Out of the 30 patients enrolled, 24 completed all the phases of the study. Six patients were lost to follow up. Mean supine and standing blood pressure and heart rate at the end of each treatment phase are shown in table 1. After the placebo run in phase, the mean (SD) supine blood pressure was 149 (10)/98 (6) mm Hg and the standing blood pressure was 155 (11)/103 (7) mm Hg. The supine and standing heart rate were 76 (6) and 77 (8) beats/min respectively. Amlodipine 2.5 mg and 5 mg produced a significant fall in both supine and standing blood pressure. Treatment with lisinopril in doses of 5 mg and 10 mg also significantly decreased supine and standing blood pressure. The mean DBP (below target 90 mm Hg) was achieved in a higher percentage of patients with 5 mg amlodipine and 10 mg lisinopril monotherapy. There was a greater reduction in systolic blood pressure (SBP) and DBP in supine and standing positions with the combination of amlodipine and lisinopril than the individual drugs. Combination of amlodipine 2.5 mg and lisinopril 5 mg reduced the mean DBP below 90 mm Hg in 54% of patients.
The mean (SD) supine blood pressure was significantly reduced from 149 (10)/98 (6) to 140 (11)/92 (7) and 137 (7)/85 (6) mm Hg with 2.5 and 5 mg amlodipine respectively (p<0.001). There was a significant fall in standing blood pressure from 155 (11)/103 (7) to 143 (12)/93 (8) and 138 (6)/88 (6) mm Hg with 2.5 and 5 mg amlodipine respectively (p<0.001).
Lisinopril at 5 mg and 10 mg also produced a significant dose dependent decrease in supine and standing blood pressure from the basal value to 138 (10)/90 (8), 136 (7)/87 (5), 40 (10)/92 (6), and 138 (9)/89 (5) mm Hg respectively (p<0.001). There was a more marked fall in blood pressure with the combination of amlodipine and lisinopril than with either drug given individually. Amlodipine 2.5 mg with 5 mg lisinopril lowered supine and standing blood pressure to 131 (9)/82 (7) and 132 (9)/83 (7) mm Hg respectively (p<0.001). Amlodipine at 5 mg plus lisinopril at 10 mg in combination produced a more significant fall in supine and standing blood pressure to 127 (9)/ 79 (5) and 129 (7)/79 (5) mm Hg respectively. The target standing DBP below 90 mm Hg could be achieved in 29%, 71%, 25%, and 72% patients with amlodipine 2.5, 5 mg and lisinopril 5 mg, 10 mg dose respectively. DBP below 90 mm Hg could be achieved in 54% and 100% patients with a combination of amlodipine 2.5 plus lisinopril 5 mg and amlodipine 5 mg plus lisinopril 10 mg respectively (fig 1) . None of the treatment regimens produced any significant change in mean heart rate. All patients tolerated the treatment schedules well without any serious side eVects. The frequency of side eVects observed with each treatment is shown in table 2. Ankle oedema was more frequent with amlodipine, while throat irritation and cough was reported with lisinopril. These particular side eVects were seen more in monotherapy and were much less frequent during combination therapy.
Discussion
Many antihypertensive agents are available in the market. Any of these drugs when used alone as a monotherapy are eVective in only 40%-60% of patients with hypertension. 7 Several studies reported that combination treatment using antihypertensive agents of two different classes are useful and promising in controlling blood pressure in patients with hypertension. 8 9 Calcium channel blockers and ACE inhibitors in combination reduce blood pressure more than either drug alone. 5 In the present study we observed more eVective lowering of blood pressure to the target value with amlodipine and lisinopril in combination. Singer et al demonstrated a greater blood pressure lowering eVect when nifedipine and captopril were combined. 5 However, they found the eVect of the combination to be short lasting. Similar observations were also made in a small group of patients who were on a captopril and nifedipine combination. 10 Although the combination was more eVective than monotherapy in lowering blood pressure, frequent dosing was required for adequate blood pressure control. 11 In the present study, the combination of long acting drugs of the two classes, namely amlodipine and lisinopril, reduced blood pressure more than either drug alone even 24 hours after dosing. This clearly shows that the combination has a marked additional and long lasting eVect on blood pressure.
In the present study, at the end of lisinopril treatment phase, 72% of patients achieved a fall in DBP to the target value and with amlodipine it could be achieved in 71% of patients.
Combination of the two drugs, irrespective of their order, reduced blood pressure to the target value in 100% of patients. Perhaps the most eYcient and conceptually attractive approach in the treatment of patients in whom ACE inhibitor or calcium channel blocker monotherapy fails, is to combine the two agents, thereby blocking the major vasoconstrictive mechanisms. 12 The eYcacy of a calcium channel blocker is enhanced by concomitant use of an ACE inhibitor, methyldopa, or -blocker. 13 Ninety per cent of patients with mild to moderate hypertension are controlled by combination of an ACE inhibitor with either a calcium channel blocker, -adrenergic receptor blocker, or diuretic.
14 Isolated systolic hypertension is a definite risk factor for cardiovascular morbidity and mortality independent of diastolic elevation. These complications include coronary artery disease, stroke, and cardiac failure. 15 Raised SBP leads to an increase in myocardial oxygen consumption with an enhanced rise of an acute coronary event, lowering of SBP, and thus might be advantageous especially in hypertensives with ischaemic heart disease. 16 In the present study, lowering of SBP with a combination of amlodipine and lisinopril will be beneficial. In a double blind placebo controlled study, 2 mg and 4 mg of a new calcium antagonist, lacidipine, were shown to cause significant reduction in SBP variability and provided adequate control of arterial hypertension. 17 The mechanism of additive eVect of these two classes of drugs used in the present study is not clear. Dihydropyridines such as nifedipine cause acute natriuresis and diuresis 18 resulting in long lasting loss of sodium and water. 19 This eVect is also likely to be present with amlodipine. 20 Loss of sodium and water leads to activation of the renin angiotensinaldosterone system, after treatment with dihydropyridine calcium antagonists, reflecting an increase in circulating concentrations of angiotension II. These eVects are likely to oVset partly the blood pressure lowering eVect of dihydropyridines. 20 Addition of an ACE inhibitor blocks the rise in angiotensin II activity and thus potentiates the eVect of calcium channel blockers on blood pressure. ACE inhibitors may also potentiate the action of dihydropyridines by buVering the baroreflex mediated increase in heart rate secondary to vasodilatation due to calcium channel blockers or by indirectly inhibiting the sympathetic nervous system.
1
Amlodipine and lisinopril monotherapy produced a similar fall in blood pressure in our study but a greater blood pressure lowering eVect was noticed with the combination of the two drugs. Morgan and Anderson reported a higher blood pressure lowering eVect with the combination of low doses of enalapril and felodipine. 6 Short acting dihydropyridines are known to produce reflex tachycardia. In the present study, amlodipine monotherapy did not produce any tachycardia, particularly in a standing position. The ACE inhibitor captopril, in combination, eVectively blocked nifedipine induced tachycardia. 10 We did not find any significant change in heart rate, suggesting that there is no significant stimulation of the sympathetic nervous system during amlodipine therapy. Cappuccio et al also reported similar results with 5 mg amlodipine in their study. 20 One advantage of combination therapy is that there is an additive eVect on blood pressure so that lower doses of both drugs can be given, mitigating side eVects. We found that the incidence both of oedema of the feet and cough was less during combination therapy than with either drug alone. Recently, a combination product containing amlodipine and benazapril has been approved for clinical use. This combination was found to be more eVective than individual monotherapy with significantly lower overall side eVects, particularly headache and oedema. 21 In a dose response relationship study, enalapril and felodipine were given alone and in combination in 707 patients and the combination was associated with less peripheral oedema than felodipine alone. 22 Similarly, ankle oedema associated with nifedipine therapy disappeared in three of four patients after the addition of captopril. 23 24 In another study, the incidence of swollen ankle was significantly more with felodipine monotherapy compared with a combination of felodipine and enalapril. 6 The combination of ACE inhibitors with calcium channel blockers may provide other special values. 25 There is evidence that reflex tachycardia associated with the dihydropyridine group is corrected by a parasympathetic influence 26 27 and that of peripheral oedema is corrected by the postcapillary or venodilating eVect of added converting enzyme inhibitor. 24 The large majority of currently marketed preparations contain a thiazide diuretic or a -blocker with a calcium channel blocker. Results of studies with more novel combinations such as ACE inhibitors and calcium channel blockers will provide a regimen that is more eVective with minimum side eVects.
